Cancer Management and Research (Jan 2022)
First-Line Anlotinib Combined with Stereotactic Body Radiation Therapy for an Octogenarian with Pulmonary Carcinosarcoma
Abstract
Long Liang,1,* Taiyu Chen,2,* Tao Ren,3 Mian Mao,4 Keli Wang,5 Chunhan Tang,2 Juan Xiao,1 Hongyuan Jia,1 Wenli Chen,1 Qifeng Wang,1 Tao Li1 1Department of Radiation Oncology, Sichuan Cancer Hospital and Institution, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Radiation Oncology Key Laboratory of Sichuan Province, Chengdu, People’s Republic of China; 2Clinical Medical College of Chengdu Medical College, Chengdu, 610500, People’s Republic of China; 3Oncology Department, Clinical Medical College and The First Affiliated Hospital of Chengdu Medical College, Chengdu, 610500, People’s Republic of China; 4Department of Pharmacy, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, People’s Republic of China; 5Clinical Medical College of Southwest Medical University, Luzhou, 646000, People’s Republic of China*These authors contributed equally to this workCorrespondence: Tao Li Tel/Fax +86 2885420173Email [email protected]: Pulmonary carcinosarcoma (PC) is a rare and highly malignant type of non-small cell lung cancer (NSCLC) that is insensitive to radiotherapy and chemotherapy and has a poor prognosis. Here, we report a case of an 88-year-old patient with inoperable PC and a history of cerebral infarction who was treated with first-line anlotinib combined with stereotactic body radiation therapy (SBRT). The therapeutic response has sustained for 10 months. Our work suggests that SBRT combined with anlotinib may be a safe and effective treatment strategy for octogenarians with PC.Keywords: pulmonary carcinosarcoma, SBRT, anlotini
